|
Orthologous residues
|
|
CK1D (human): S370‑p, CK1D iso2 (human): S370‑p, CK1D (mouse): S370‑p, CK1D iso2 (mouse): S370‑p, CK1D (rat): S370‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, phospho-antibody, western blotting
|
|
Disease tissue studied:
pancreatic cancer, pancreatic carcinoma
|
|
Relevant cell lines - cell types - tissues:
MIA PaCa (pancreatic)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Comments:
weakly phosphorylatd by PKCA and CLK2
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACA (human)
|
pharmacological inhibitor of upstream enzyme, 2D analysis, phosphopeptide analysis
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
H-89
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, intracellular localization
|
